Bjarke Henric Bjorn

Chief Executive Officer

C-suiteM

US·SEC (Form 4)

Inozyme Pharma, Inc.

0

Total declarations

0

Company

€92,639

▲ Purchases (1 ops.)

—

▼ Sales (0 ops.)

Discover the complete record of transactions filed by Bjarke Henric Bjorn, Chief Executive Officer. Insider active across 1 companies, notably Inozyme Pharma, Inc.. Cumulatively, 1 disclosures have been logged. Total volume traded: €93k. The latest transaction was filed on 19 April 2022 — Acquisition. Regulator: SEC (Form 4). The full history is openly available.

Declarations1 total

Executives▲PurchaseIInozyme Pharma, Inc.41SEC

B

Bjarke Henric BjornSVP, COO

€92,63927,100 shares@ €3.4184100.0% of flow

Common Stock

SEC:0001209191-22-024918:0·19 Apr 2022

Ideal exit: 14 Jan 2023 (T+270)

SEC ↗

1 of 1 declaration

About Bjarke Henric Bjorn

Henric Bjorn Bjarke is the SVP and COO at Inozyme Pharma, Inc. He is responsible for overseeing the company's operations, ensuring efficiency and process optimization. His experience in the industry enables him to lead strategic initiatives to enhance operational performance.